Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christer Norman is active.

Publication


Featured researches published by Christer Norman.


Lancet Infectious Diseases | 2008

Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme

Sigvard Mölstad; Mats Erntell; Håkan Hanberger; Eva Melander; Christer Norman; Gunilla Skoog; C. Stålsby Lundborg; A. Söderström; E. Torell; O Cars

Increasing use of antibiotics and the spread of resistant pneumococcal clones in the early 1990s alarmed the medical profession and medical authorities in Sweden. Strama (Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance) was therefore started in 1994 to provide surveillance of antibiotic use and resistance, and to implement the rational use of antibiotics and development of new knowledge. Between 1995 and 2004, antibiotic use for outpatients decreased from 15.7 to 12.6 defined daily doses per 1000 inhabitants per day and from 536 to 410 prescriptions per 1000 inhabitants per year. The reduction was most prominent in children aged 5-14 years (52%) and for macrolides (65%). During this period, the number of hospital admissions for acute mastoiditis, rhinosinusitis, and quinsy (peritonsillar abscess) was stable or declining. Although the epidemic spread in southern Sweden of penicillin-resistant Streptococcus pneumoniae was curbed, the national frequency increased from 4% to 6%. Resistance remained low in most other bacterial species during this period. This multidisciplinary, coordinated programme has contributed to the reduction of antibiotic use without measurable negative consequences. However, antibiotic resistance in several bacterial species is slowly increasing, which has led to calls for continued sustained efforts to preserve the effectiveness of available antibiotics.


Bulletin of The World Health Organization | 2017

Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance

Sigvard Mölstad; Sonja Löfmark; Karin Carlin; Mats Erntell; Olov Aspevall; Lars Blad; Håkan Hanberger; Katarina Hedin; Jenny Hellman; Christer Norman; Gunilla Skoog; Cecilia Stålsby-Lundborg; Karin Tegmark Wisell; Christina Åhréni; Otto Cars

Abstract Increasing use of antibiotics and rising levels of bacterial resistance to antibiotics are a challenge to global health and development. Successful initiatives for containing the problem need to be communicated and disseminated. In Sweden, a rapid spread of resistant pneumococci in the southern part of the country triggered the formation of the Swedish strategic programme against antibiotic resistance, also known as Strama, in 1995. The creation of the programme was an important starting point for long-term coordinated efforts to tackle antibiotic resistance in the country. This paper describes the main strategies of the programme: committed work at the local and national levels; monitoring of antibiotic use for informed decision-making; a national target for antibiotic prescriptions; surveillance of antibiotic resistance for local, national and global action; tracking resistance trends; infection control to limit spread of resistance; and communication to raise awareness for action and behavioural change. A key element for achieving long-term changes has been the bottom-up approach, including working closely with prescribers at the local level. The work described here and the lessons learnt could inform countries implementing their own national action plans against antibiotic resistance.


BMJ Open | 2017

Antibiotic use and bacterial complications following upper respiratory tract infections: a population-based study

Thomas Cars; Irene Eriksson; Anna Granath; Björn Wettermark; Jenny Hellman; Christer Norman; Anders Ternhag

Objectives To investigate if use of antibiotics was associated with bacterial complications following upper respiratory tract infections (URTIs). Design Ecological time-trend analysis and a prospective cohort study. Setting Primary, outpatient specialist and inpatient care in Stockholm County, Sweden. All analyses were based on administrative healthcare data on consultations, diagnoses and dispensed antibiotics from January 2006 to January 2016. Main outcome measures Ecological time-trend analysis: 10-year trend analyses of the incidence of URTIs, bacterial infections/complications and respiratory antibiotic use. Prospective cohort study: Incidence of bacterial complications following URTIs in antibiotic-exposed and non-exposed patients. Results The utilisation of respiratory tract antibiotics decreased by 22% from 2006 to 2015, but no increased trend for mastoiditis (p=0.0933), peritonsillar abscess (p=0.0544), invasive group A streptococcal disease (p=0.3991), orbital abscess (p=0.9637), extradural and subdural abscesses (p=0.4790) and pansinusitis (p=0.3971) was observed. For meningitis and acute ethmoidal sinusitis, a decrease in the numbers of infections from 2006 to 2015 was observed (p=0.0038 and p=0.0003, respectively), and for retropharyngeal and parapharyngeal abscesses, an increase was observed (p=0.0214). Bacterial complications following URTIs were uncommon in both antibiotic-exposed (less than 1.5 per 10 000 episodes) and non-exposed patients (less than 1.3 per 10 000 episodes) with the exception of peritonsillar abscess after tonsillitis (risk per 10 000 tonsillitis episodes: 32.4 and 41.1 in patients with no antibiotic treatment and patients treated with antibiotics, respectively). Conclusions Bacterial complications following URTIs are rare, and antibiotics may lack protective effect in preventing bacterial complications. Analyses of routinely collected administrative healthcare data can provide valuable information on the number of URTIs, antibiotic use and bacterial complications to patients, prescribers and policy-makers.


Läkartidningen | 2009

[In common infections: to give or not to give antibiotics].

Sigvard Mölstad; Malin André; Christer Norman; Katarina Hedin; Sven Engström


BMC Infectious Diseases | 2016

A randomized controlled study of 5 and 10 days treatment with phenoxymethylpenicillin for pharyngotonsillitis caused by streptococcus group A – a protocol study

Gunilla Skoog; Charlotta Edlund; Christian G. Giske; Sigvard Mölstad; Christer Norman; Pär-Daniel Sundvall; Katarina Hedin


Läkartidningen | 2010

Bakteriella hud- och mjukdelsinfektioner i primärvård: Mindre antibiotika i sikte med nya rekommendationer

Christer Norman; Sigvard Mölstad


Läkartidningen | 2010

Antibiotika eller inte - prokalcitonin kan vägleda behandlingsval : Åtminstone på akuten för vuxna med nedre luftvägsinfektion

Anders Ternhag; Otto Cars; Christer Norman; Johan Struwe


Läkartidningen | 2007

STRAMA håller fast vid Otitkonsensus

Christer Norman; Otto Cars; Ann Söderström; Anita Groth; Ann Hermansson


Läkartidningen | 2012

Replik från Smittskyddsinstitutet och Strama-rådet : Nationella rekommendationer för behandling av faryngotonsillit gäller

Otto Cars; Sigvard Mölstad; Christer Norman; Anders Ternhag; Malin André; Mats Erntell


Läkartidningen | 2009

Doxycyklin är ingen ­hostmedicin: Antibiotika vid akut bronkit är både onödigt och riskabelt

Åke Örtqvist; Hans Holmberg; Christer Norman; Otto Cars

Collaboration


Dive into the Christer Norman's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gunilla Skoog

Public Health Agency of Sweden

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Johan Struwe

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

E. Torell

Uppsala University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge